Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical

Overview

Journal Infection

Date 2010 Jan 29

PMID 20107858

Citations 23

Authors

J M Leitner

W Graninger

F Thalhammer

Affiliations

Soon will be listed here.

Abstract

Drug-induced hepatotoxicity is a frequent cause of liver disease and acute liver failure, particularly in patients treated with multiple drugs. Several antibacterial drugs have the potential to cause severe liver injury and failure. This article aims to increase the awareness and understanding of drug induced liver injury (DILI) due to antibacterial drugs. It reviews the pattern of antibacterial DILI and provides details on molecular mechanisms and toxicogenomics, as well as clinical data based on epidemiology studies. Certain antibacterial drugs are more frequently linked to hepatotoxicity than others. Therefore, the hepatotoxic potential of tetracyclines,sulfonamides, tuberculostatic agents, macrolides, quinolones,and beta-lactams are discussed in more detail. Efforts to improve the early detection of DILI and the acquisition of high-quality epidemiological data are pivotal for increased patient safety.

Citing Articles

An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study.

Shiraishi C, Kato H, Ogura T, Iwamoto T Sci Rep. 2024; 14(1):18221.

PMID: 39107511 PMC: 11303562. DOI: 10.1038/s41598-024-69279-6.

Expert consensus on endodontic therapy for patients with systemic conditions.

Xu X, Zheng X, Lin F, Yu Q, Hou B, Chen Z Int J Oral Sci. 2024; 16(1):45.

PMID: 38886374 PMC: 11183232. DOI: 10.1038/s41368-024-00312-0.

Genetic Variations and Antibiotic-Related Adverse Events.

Principi N, Petropulacos K, Esposito S Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543117 PMC: 10974439. DOI: 10.3390/ph17030331.

Safety of fluoroquinolones.

Barberan J, de la Cuerda A, Tejeda Gonzalez M, Lopez Aparicio A, Monfort Vinuesa C, Ramos Sanchez A Rev Esp Quimioter. 2023; 37(2):127-133.

PMID: 38140798 PMC: 10945095. DOI: 10.37201/req/143.2023.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

References

Carson J, Strom B, Duff A, Gupta A, Shaw M, Lundin F . Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993; 119(7 Pt 1):576-83. DOI: 10.7326/0003-4819-119-7_part_1-199310010-00005. View

Lee S, Buters J, Pineau T, Gonzalez F . Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem. 1996; 271(20):12063-7. DOI: 10.1074/jbc.271.20.12063. View

Rubinstein E . History of quinolones and their side effects. Chemotherapy. 2001; 47 Suppl 3:3-8; discussion 44-8. DOI: 10.1159/000057838. View

Andrade R, Lucena M, Fernandez M, Pelaez G, Pachkoria K, Garcia-Ruiz E . Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2):512-21. DOI: 10.1016/j.gastro.2005.05.006. View

Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B . Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol. 2006; 63(1):73-9. DOI: 10.1007/s00228-006-0222-z. View

Navarro V, Senior J . Drug-related hepatotoxicity. N Engl J Med. 2006; 354(7):731-9. DOI: 10.1056/NEJMra052270. View

Boudreaux J, Hayes D, Mizrahi S, Hussey J, Regenstein F, Balart L . Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc. 1993; 25(2):1873. View

Derby L, Jick H, Henry D, Dean A . Cholestatic hepatitis associated with flucloxacillin. Med J Aust. 1993; 158(9):596-600. DOI: 10.5694/j.1326-5377.1993.tb137624.x. View

Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C . An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174(8):935-52. DOI: 10.1164/rccm.200510-1666ST. View

10.

Lee W . Drug-induced hepatotoxicity. N Engl J Med. 2003; 349(5):474-85. DOI: 10.1056/NEJMra021844. View

11.

Pugh A, Barve A, Falkner K, Patel M, McClain C . Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis. 2009; 13(2):277-94. DOI: 10.1016/j.cld.2009.02.008. View

12.

Christopher K, Hyatt P, Horkan C, Yodice P . Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol. 2002; 97(2):489-90. DOI: 10.1111/j.1572-0241.2002.05505.x. View

13.

Christiansen K . Fusidic acid adverse drug reactions. Int J Antimicrob Agents. 1999; 12 Suppl 2:S3-9. DOI: 10.1016/s0924-8579(98)00068-5. View

14.

Polson J . Hepatotoxicity due to antibiotics. Clin Liver Dis. 2007; 11(3):549-61, vi. DOI: 10.1016/j.cld.2007.06.009. View

15.

Wagner M, Zollner G, Trauner M . New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009; 51(3):565-80. DOI: 10.1016/j.jhep.2009.05.012. View

16.

Brinker A, Wassel R, Lyndly J, Serrano J, Avigan M, Lee W . Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology. 2008; 49(1):250-7. DOI: 10.1002/hep.22620. View

17.

Shlaes D, Moellering R . Telithromycin and the FDA: implications for the future. Lancet Infect Dis. 2008; 8(2):83-5. DOI: 10.1016/S1473-3099(08)70002-1. View

18.

. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003; 52(31):735-9. View

19.

Carbon C . [Levofloxacin adverse effects, data from clinical trials and pharmacovigilance]. Therapie. 2001; 56(1):35-40. View

20.

Fuchs M, Sanyal A . Sepsis and cholestasis. Clin Liver Dis. 2008; 12(1):151-72, ix. DOI: 10.1016/j.cld.2007.11.002. View